[go: up one dir, main page]

MA30312B1 - Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant - Google Patents

Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Info

Publication number
MA30312B1
MA30312B1 MA31195A MA31195A MA30312B1 MA 30312 B1 MA30312 B1 MA 30312B1 MA 31195 A MA31195 A MA 31195A MA 31195 A MA31195 A MA 31195A MA 30312 B1 MA30312 B1 MA 30312B1
Authority
MA
Morocco
Prior art keywords
same
pharmaceutical compositions
compositions containing
preparing
rimonabant monohydrate
Prior art date
Application number
MA31195A
Other languages
English (en)
Inventor
Olivier Monnier
Gerard Coquerel
Baptiste Fours
Helene Duplaa
Philippe Ochsenbein
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30312(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30312B1 publication Critical patent/MA30312B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet le monohydrate de rimonabant, son procédé de préparation et les compositions pharmaceutiques en contenant.
MA31195A 2006-02-08 2008-08-26 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant MA30312B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601253A FR2897060B1 (fr) 2006-02-08 2006-02-08 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
MA30312B1 true MA30312B1 (fr) 2009-04-01

Family

ID=37075667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31195A MA30312B1 (fr) 2006-02-08 2008-08-26 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Country Status (20)

Country Link
US (1) US20090048449A1 (fr)
EP (1) EP1984341A1 (fr)
JP (1) JP2009526025A (fr)
KR (1) KR20080093042A (fr)
CN (1) CN101405271A (fr)
AR (1) AR059327A1 (fr)
AU (1) AU2007213649A1 (fr)
BR (1) BRPI0707711A2 (fr)
CA (1) CA2641494A1 (fr)
DO (1) DOP2007000023A (fr)
EA (1) EA200870236A1 (fr)
FR (1) FR2897060B1 (fr)
GT (1) GT200700014A (fr)
IL (1) IL192963A0 (fr)
MA (1) MA30312B1 (fr)
NO (1) NO20083521L (fr)
TW (1) TW200804343A (fr)
UY (1) UY30137A1 (fr)
WO (1) WO2007090949A1 (fr)
ZA (1) ZA200806713B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008056377A2 (fr) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Nouvelles formes du rimonabant
PT3229799T (pt) * 2014-12-08 2019-01-29 Crystal Pharmatech Co Ltd Formas cristalinas de complexo supramolecular trissódico compreendendo valsartan e ahu-377 e métodos das mesmas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP4746931B2 (ja) * 2005-07-22 2011-08-10 株式会社日立製作所 フラットディスプレイパネルモジュール及びフラットディスプレイ装置
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008035023A1 (fr) * 2006-09-19 2008-03-27 Cipla Limited Formes polymorphes de rimonabant

Also Published As

Publication number Publication date
KR20080093042A (ko) 2008-10-17
WO2007090949A1 (fr) 2007-08-16
GT200700014A (es) 2007-09-19
IL192963A0 (en) 2009-02-11
NO20083521L (no) 2008-10-24
AR059327A1 (es) 2008-03-26
DOP2007000023A (es) 2008-02-15
ZA200806713B (en) 2009-10-28
EA200870236A1 (ru) 2009-02-27
BRPI0707711A2 (pt) 2011-05-10
JP2009526025A (ja) 2009-07-16
FR2897060B1 (fr) 2008-07-25
AU2007213649A1 (en) 2007-08-16
UY30137A1 (es) 2007-09-28
CA2641494A1 (fr) 2007-08-16
US20090048449A1 (en) 2009-02-19
CN101405271A (zh) 2009-04-08
FR2897060A1 (fr) 2007-08-10
EP1984341A1 (fr) 2008-10-29
TW200804343A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
MX2009000884A (es) Derivados de piridizinona.
TW200800997A (en) Chemical compounds
MX2009001062A (es) Agonistas de ep2.
MX2009005357A (es) Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz.
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
MX2011012122A (es) Derivados de tiofeno.
EP2364983A4 (fr) Nouveau dérivé tricyclique ou ses sels pharmaceutiquement acceptables, son procédé de préparation, et composition pharmaceutique le contenant
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MA30312B1 (fr) Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
EP2241571A4 (fr) 6-méthoxy-2',3'-didésoxyguanosine stable, son procédé de préparation et composition pharmaceutique la contenant
EA200900622A1 (ru) Фармацевтическая композиция, содержащая полиморфную форму 1 клопидогрела гидросульфата